Status:
TERMINATED
Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy
Lead Sponsor:
Novartis
Conditions:
Diabetic Gastropathy
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study is being done to evaluate the safety, tolerability and satisfactory relief of tegaserod against dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy.
Eligibility Criteria
Inclusion
- History of Type 1 or insulin-requiring Type 2 diabetes for at least 3 years
- GI symptoms for at least 2 months before entering study
Exclusion
- Very high body weight
- Significant diarrhea
- Ulcers
- Symptom severity score collected via diary Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2005
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00142974
Start Date
May 1 2004
End Date
April 1 2005
Last Update
April 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Basel, Switzerland, 4056